Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir
Daniel Camprubí, Anna Gayà, María Ángeles Marcos, Helena Martí-Soler, Àlex Soriano, Mar Mosquera, Aina Oliver‐Caldés, Marta Santos Bravo, José Muñóz, Carolina García‐Vidal
Abstract
Microbiological response of SARS-CoV-2 to remdesivir in immunocompromised patients has not been evaluated. We present the case of a severely immunocompromised patient with persistent replication of SARS-CoV-2, who required different courses of remdesivir. Short courses of remdesivir might be insufficient in immunocompromised patients due to prolonged viral clearance.
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Replication (statistics)Coronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakMedicineViral replicationImmunosuppressionImmunologyIntensive care medicineVirusInternal medicineInfectious disease (medical specialty)OutbreakDiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing